ANI Pharmaceuticals will acquire Alimera Sciences in a deal that values the firm at $381m in upfront consideration, after signing a definitive agreement in a move that is seen as an effort to gain a foothold in ophthalmology and expand its rare diseases business.
ANI Acquires Alimera Sciences To Bolster Ophthalmology Portfolio
The Move Reflects ANI’s Ambition To Increase Foothold In Rare Disease
ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.
